EndoSonics to initiate direct sales
Intravascular ultrasound developer EndoSonics has reached an agreement in principle with the Cordis division of Johnson & Johnson to end that company's role as exclusive distributor of certain EndoSonics products in the U.S., Europe, the Middle East,
Intravascular ultrasound developer EndoSonics has reached an agreement in principle with the Cordis division of Johnson & Johnson to end that company's role as exclusive distributor of certain EndoSonics products in the U.S., Europe, the Middle East, and Africa. Assuming completion of a definitive agreement, EndoSonics will launch its own distribution strategy, which will consist of direct sales in some locations, as well as alliances with regional distributors, according to the Rancho Cordova, CA-based firm.
EndoSonics made the move to terminate the Cordis relationship in response to declines in orders from the company in recent quarters. Despite several initiatives by both companies to increase sales, the firms have mutually decided to end the distribution relationship, said Reinhard Warnking, EndoSonics president and CEO.
In other EndoSonics news, the company reported revenue of $9 million in its first quarter (end-March), an increase of 42.6% compared with the $6.3 million reported in the same period last year. The firm reported a net loss of $1.1 million, however, compared with a profit of $505,000 posted in the first quarter of 1997.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
